ROYAL SOCIETY OPEN SCIENCE

royalsocietypublishing.org/journal/rsos

Research





Cite this article: Orhobor OI, Rehim AA, Lou H, Ni H, King RD. 2022 A simple spatial extension to the extended connectivity interaction features for binding affinity prediction. *R. Soc. Open Sci.* **9**: 211745.

https://doi.org/10.1098/rsos.211745

Received: 8 November 2021 Accepted: 13 April 2022

Subject Category:

Biochemistry, cellular and molecular biology

Subject Areas:

biotechnology/bioinformatics

Keywords:

machine learning, protein binding affinity prediction, scoring functions

Author for correspondence:

Oghenejokpeme I. Orhobor e-mail: oghenejokpeme.orhobor@gmail.com

Electronic supplementary material is available online at https://doi.org/10.6084/m9.figshare.c. 5958909.

THE ROYAL SOCIETY PUBLISHING

A simple spatial extension to the extended connectivity interaction features for binding affinity prediction

Oghenejokpeme I. Orhobor¹, Abbi Abdel Rehim¹, Hang Lou³, Hao Ni^{3,4} and Ross D. King^{1,2,4}

OIO, 0000-0003-1178-611X; RDK, 0000-0001-7208-4387

The representation of the protein-ligand complexes used in building machine learning models play an important role in the accuracy of binding affinity prediction. The Extended Connectivity Interaction Features (ECIF) is one such representation. We report that (i) including the discretized distances between protein-ligand atom pairs in the ECIF scheme improves predictive accuracy, and (ii) in an evaluation using gradient boosted trees, we found that the resampling method used in selecting the best hyperparameters has a strong effect on predictive performance, especially for benchmarking purposes.

1. Background

It is commonplace to estimate the binding affinity of proteinligand complexes using *in silico* scoring functions (models) built using statistical machine learning (ML) algorithms [1,2]. ML model performance on any predictive task largely depends on the quality of the descriptors used in building it. Therefore, one can argue that the performance of a scoring function is predicated on two key components: (i) the choice of ML algorithm and (ii) the quality of the input descriptors.

Among the many ML algorithms that have been used in constructing scoring functions [3–6], gradient boosted trees (GBTs) have been identified as one of the top performers [4,7,8]. Like most sophisticated ML algorithms, GBTs have several hyperparameters that require tuning to achieve the best performance on a given problem. The selection of the best hyperparameters usually involves a search through the hyperparameter space and their

© 2022 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original author and source are credited.

¹Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK

²Department of Biology and Biological Engineering, Chalmers University of Technology, Göteborg, Sweden

³Department of Mathematics, University College London, London, UK

⁴The Alan Turing Institute, London, UK

quality tested using some form of resampling [9]. While several search strategies for hyperparameter selection have been proposed [10], this is not the focus of this work. Here, we focus on the effect of resampling technique in the identification of optimal hyperparameters. We demonstrate empirically that the choice of resampling technique has strong effects on the choice of optimal hyperparameters, and by extension, the performance of a constructed scoring function. Although this is well known in the ML community, it is often a footnote or ignored in the protein-binding affinity prediction literature.

Several descriptors for the representation of protein-ligand complexes for use in building ML-based scoring functions have been proposed [8,11]. These descriptors often implement principles from extended connectivity fingerprints [12]. A recent approach which has been shown to achieve state-of-the-art performance is the extended connectivity interaction features [8] (ECIF), which identified 22 atom-types for proteins, and 70 atom-types for ligands based on connectivity. Pairs of these protein-ligand atom-types within a distance threshold are used as descriptors, where the value for each protein-ligand complex is the frequency of its occurrence. In this work, we extend this approach by distinguishing between shorter and longer descriptor interactions, and refer to this approach as pair distance ECIF (PDECIF). We evaluated the proposed approach using the comparative assessment of scoring functions (CASF) family of benchmark datasets [5,13,14], and demonstrate that PDECIF outperforms ECIF when paired with GBTs. Our contributions are as follows:

- We demonstrate the effect the choice of resampling technique when optimizing ML algorithm hyperparameters has on scoring function performance. Our analysis shows that the difference in predictive performance is not statistically significant. However, it is worth noting that the observed differences are indeed important, especially when comparing the performance of different scoring functions.
- We propose PDECIF, an extension to ECIF which outperforms its predecessor.

2. Methods

2.1. ECIF and PDECIF

A ligand descriptor in the ECIF framework consists of an atom's symbol, explicit valence, number of attached heavy atoms, number of attached hydrogens, aromaticity and ring membership. Each of these properties can be represented textually where each property is separated by a semicolon. For example C;4;3;0;0;0. Protein descriptors are formulated in the same way where Protein Data Bank (PDB) residue and atom pairs map to an ECIF atom of the same form. For example, ASN-OXT maps to O;2;1;0;0;0. Given a protein-ligand complex and under a prespecified distance threshold, for example 6 Å, a valid ECIF descriptor consists of a protein-ligand atom pair of the form C;4;3;0;0;0-O;2;1;0;0;0. The assigned numerical value is the number of times it occurs in the complex under the distance threshold. In total, there are 1540 of such pairs, see the original work for the complete set [8]. In contrast to ECIF, rather than specify a maximum distance, we specify a distance below which we consider short and above which we consider long. The distance for long-range interactions is uncapped. So using the example for the ECIF descriptor above, we have the following descriptors for short and long, respectively; C;4;3;0;0;0-O;2;1;0;0;0-1 and C;4;3;0;0;0-O;2;1;0;0;0-h. Note that the choice of '-l' and '-h' are simply as delineating symbols for the distances and have no intrinsic meaning.

2.2. Datasets

We performed our evaluation using the CASF 2007, 2013, 2016 and 2019 benchmark datasets [5,13,14]. They all have independent train and test sets, with 1090–210, 2764–195, 3772–285 and 9291–285 traintest samples for the aforementioned datasets, respectively. We used this existing split in our experiments. Note that the CASF 2019 set shares the same test set as the CASF 2016 set, albeit with more training samples. We read the raw data from PDBbind; where RDKit was incapable of reading the ligand files, Open Babel (v. 3.1.1) was used to convert these into mol files that were fully compatible with RDKit. All files were then saved in mol format before use. We considered four distance thresholds for both ECIF and PDECIF: 4 Å, 6 Å, 8 Å and 10 Å. Table 1 shows the number of features generated using ECIF and PDECIF at the different distance thresholds for the benchmark datasets. Note that the number of features for the ECIF datasets is never up to the reported 1540 in the original. This is because we only included features for which at least one complex has a non-zero value. We also considered a case were the ECIF and PDECIF datasets are augmented with 194 ligand features [15] generated using RDKit. The features are described in electronic supplementary material, S1.

royalsocietypublishing.org/journal/rsos

R.

Soc. Open Sci. 9: 211745

Table 1. The number of features generated for each of the benchmark datasets using the ECIF and PDECIF approaches at different distances (angstroms).

benchmark	distance	ECIF	PDECIF
CASF 2007	4	856	2178
	6	1161	2482
	8	1244	2563
	10	1285	2595
CASF 2013	4	996	2290
	6	1226	2520
	8	1268	2561
	10	1288	2579
CASF 2016	4	1078	2485
	6	1332	2739
	8	1376	2781
	10	1399	2803
CASF 2019	4	1176	2584
	6	1362	2770
	8	1389	2795
	10	1402	2807

Table 2. *P*-values from paired *t*-test statistical testing of the difference in predictive performance (*R*) between the considered representations across the different resampling methods.

representation pairs	train-test	CV5	CV10
ECIF — ECIF + Ligand	9.369×10^{-5}	1.918×10^{-4}	1.502×10^{-4}
ECIF — PDECIF	2.133×10^{-3}	6.220×10^{-3}	6.419×10^{-3}
ECIF — PDECIF + Ligand	5.471×10^{-5}	1.271×10^{-4}	1.391×10^{-4}
ECIF + Ligand — PDECIF	5.364×10^{-1}	1.388×10^{-1}	1.188×10^{-1}
ECIF + Ligand — PDECIF + Ligand	6.175×10^{-3}	5.564×10^{-4}	3.924×10^{-3}
PDECIF — PDECIF + Ligand	3.688×10^{-5}	6.243×10^{-8}	1.052×10^{-6}

2.3. Evaluation set-up

We used GBT as our learner of choice. The hyperparameters were optimized using a grid search, and kept all but the number of rounds, max depth and learning rate as default values, where the number of rounds = (500, 1000, 1500, 2000), max depth = (2, 4, 6, 8) and learning rate = (0.001, 0.01, 0.1, 0.2, 0.3). Selection of the best combination of these parameters was performed using only the *training data* for each of the benchmarks. We considered three resampling approaches; train–test split (70-30%) and cross-validation (CV) with k = (5, 10). These were performed once and without repetition. Having identified the best performing hyperparameters and building the final model, we report the Pearson correlation coefficient (R) and root mean square error (RMSE). For both of the performance metrics, we report model performance on each benchmark's test set. We performed feature selection on the overall best performing benchmark dataset and representation method pair using the Boruta algorithm [16] with a maximum of 500 runs, a p-value of 0.01, and a random forests [17] backend. The code used in generating the datasets and performing the experiments is available at https://github.com/oghenejokpeme/PDECIF. Links to all datasets used are also provided in the aforementioned repository.

Table 3. Predictive performance (R/RMSE) for the ECIF and PDECIF representations with and without the ligand features for the CASF 2007 and 2013 benchmark datasets when the hyperparameters for the predictive model are selected using the train—test and cross-validation ($k = \{5, 10\}$) resampling methods. For each benchmark year and distance pair, the best performing representation (with and without ligand features) and resampling method is in italics. The overall best performing combination for the given benchmark dataset is in boldface.

year—distance	representation	train—test	CV5	CV10
CASF 2007—4	ECIF	0.739/1.663	0.736/1.665	0.729/1.692
	PDECIF	0.811/1.458	0.807/1.468	0.802/1.482
	ECIF + ligand	0.759/1.583	0.787/1.562	0.783/1.562
	PDECIF + ligand	0.811/1.467	0.817/1.468	0.812/1.471
CASF 2007—6	ECIF	0.812/1.472	0.808/1.498	0.821/1.450
	PDECIF	0.803/1.494	0.808/1.467	0.806/1.472
	ECIF + ligand	0.814/1.459	0.820/1.455	0.812/1.460
	PDECIF + ligand	0.823/1.430	0.826/1.428	0.817/1.446
CASF 2007—8	ECIF	0.805/1.468	0.813/1.449	0.815/1.446
	PDECIF	0.816/1.455	0.812/1.450	0.811/1.460
	ECIF + ligand	0.815/1.472	0.818/1.443	0.820/1.442
	PDECIF + ligand	0.827/1.418	0.825/1.418	0.828/1.408
CASF 2007—10	ECIF	0.811/1.473	0.820/1.429	0.811/1.448
	PDECIF	0.811/1.476	0.808/1.476	0.807/1.481
	ECIF + ligand	0.802/1.496	0.820/1.461	0.817/1.438
	PDECIF + ligand	0.814/1.486	0.822/1.444	0.818/1.440
CASF 2013—4	ECIF	0.708/1.629	0.694/1.655	0.717/1.613
	PDECIF	0.762/1.522	0.773/1.499	0.779/1.490
	ECIF + ligand	0.777/1.484	0.776/1.480	0.778/1.481
	PDECIF + ligand	0.800/1.432	0.798/1.431	0.801/1.429
CASF 2013—6	ECIF	0.772/1.484	0.779/1.475	0.774/1.478
	PDECIF	0.792/1.449	0.786/1.461	0.783/1.467
	ECIF + ligand	0.801/1.419	0.791/1.437	0.790/1.439
	PDECIF + ligand	0.811/1.405	0.802/1.420	0.817/1.384
CASF 2013—8	ECIF	0.772/1.487	0.769/1.497	0.772/1.483
	PDECIF	0.774/1.485	0.784/1.459	0.783/1.465
	ECIF + ligand	0.799/1.420	0.797/1.423	0.799/1.422
	PDECIF + ligand	0.800/1.420	0.804/1.410	0.806/1.402
CASF 2013—10	ECIF	0.781/1.464	0.779/1.469	0.786/1.458
	PDECIF	0.780/1.469	0.775/1.478	0.778/1.472
	ECIF + ligand	0.800/1.420	0.798/1.416	0.809/1.396
	PDECIF + ligand	0.798/1.421	0.796/1.424	0.797/1.423

3. Results and discussion

3.1. Comparison of ECIF and PDECIF

Our results show that PDECIF generally outperforms ECIF. This is irrespective of distance, the presence of ligand features or the resampling method used in tuning the predictive model. We also observed that the best performing representation for all the benchmark years included the ligand features, albeit at different distance thresholds. Crucially, we wanted to know if (i) the resampling method used in

Table 4. Predictive performance (R/RMSE) for the ECIF and PDECIF representations with and without the ligand features for the CASF 2016 and 2019 benchmark datasets when the hyperparameters for the predictive model are selected using the train—test and cross-validation ($k = \{5, 10\}$) resampling methods. For each benchmark year and distance pair, the best performing representation (with and without ligand features) and resampling method is in italics. The overall best performing combination for the given benchmark dataset is in boldface.

CASE 2016—4 ECIF PDECIF 0.752/1.497 0.752/1.495 0.748/1.501 POECIF PDECIF 0.816/1.334 0.823/1.317 0.818/1.329 POECIF + ligand 0.818/1.335 0.822/1.319 0.822/1.323 CASF 2016—6 ECIF F ligand 0.841/1.272 0.840/1.273 0.839/1.275 CASF 2016—6 ECIF PDECIF 0.808/1.343 0.811/1.335 0.802/1.333 CASF 2016—8 ECIF + ligand 0.840/1.263 0.840/1.260 0.829/1.293 CASF 2016—8 ECIF F ligand 0.843/1.252 0.840/1.256 0.844/1.248 CASF 2016—8 ECIF PDECIF PDECIF 0.823/1.303 0.829/1.290 0.824/1.305 CASF 2016—8 ECIF PDECIF	year—distance	representation	train—test	CV5	CV10
ECIF + ligand 0.818/1,335 0.822/1,319 0.822/1,321 PDECIF + ligand 0.841/1,272 0.840/1,273 0.839/1,275 CASF 2016—6 ECIF 0.808/1,343 0.811/1,335 0.802/1,333 PDECIF 0.833/1,277 0.833/1,280 0.828/1,293 ECIF + ligand 0.840/1,263 0.840/1,258 0.844/1,248 CASF 2016—8 ECIF 0.806/1,343 0.804/1,350 0.797/1,361 PDECIF 0.823/1,303 0.829/1,290 0.824/1,305 ECIF + ligand 0.831/1,281 0.832/1,275 0.838/1,253 PDECIF + ligand 0.831/1,281 0.832/1,275 0.838/1,253 CASF 2016—10 ECIF 0.815/1,320 0.812/1,328 0.816/1,314 PDECIF + ligand 0.825/1,298 0.823/1,300 0.830/1,286 CASF 2019—4 ECIF 0.825/1,295 0.844/1,245 0.842/1,252 0.842/1,252 0.842/1,252 0.842/1,252 0.842/1,252 0.842/1,252 0.842/1,252 0.842/1,252 0.842/1,252 0.842/1,252 0.842/1,252 0.842/1,252 0.842/	CASF 2016—4	ECIF	0.752/1.497	0.752/1.495	0.748/1.501
PDECIF + ligand 0.841/1.272 0.840/1.273 0.839/1.275 CASF 2016—6 ECIF 0.808/1.343 0.811/1.335 0.802/1.353 PDECIF 0.833/1.277 0.833/1.280 0.828/1.293 ECIF + ligand 0.840/1.263 0.840/1.260 0.829/1.284 PDECIF + ligand 0.843/1.252 0.840/1.258 0.844/1.248 CASF 2016—8 ECIF 0.806/1.343 0.804/1.350 0.797/1.361 PDECIF 0.823/1.303 0.829/1.290 0.824/1.305 ECIF + ligand 0.831/1.281 0.832/1.275 0.838/1.263 PDECIF + ligand 0.831/1.281 0.832/1.282 0.842/1.252 CASF 2016—10 ECIF 0.815/1.320 0.812/1.338 0.816/1.314 PDECIF + ligand 0.825/1.298 0.823/1.300 0.830/1.288 CASF 2019—4 ECIF + ligand 0.844/1.245 0.842/1.252 0.844/1.246 0.839/1.204 CASF 2019—4 ECIF + ligand 0.859/1.235 0.853/1.239 0.851/1.240 CASF 2019—6 ECIF + ligand 0.859/1.235 0.853/1.23<		PDECIF	0.816/1.334	0.823/1.317	0.818/1.329
CASF 2016—6 ECIF 0.808/1.343 0.811/1.335 0.802/1.353 PDECIF 0.833/1.277 0.833/1.280 0.828/1.293 ECIF + ligand 0.840/1.263 0.840/1.260 0.829/1.284 PDECIF + ligand 0.843/1.252 0.840/1.258 0.844/1.248 CASF 2016—8 ECIF 0.806/1.343 0.804/1.350 0.797/1.361 PDECIF 0.823/1.303 0.829/1.290 0.824/1.305 ECIF + ligand 0.831/1.281 0.832/1.275 0.838/1.263 PDECIF + ligand 0.831/1.276 0.843/1.248 0.842/1.256 CASF 2016—10 ECIF 0.815/1.320 0.812/1.328 0.816/1.314 PDECIF 0.825/1.298 0.823/1.300 0.830/1.288 ECIF + ligand 0.844/1.245 0.842/1.252 0.842/1.256 CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF 0.854/1.235 0.853/1.239 0.851/1.249 ECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF <		ECIF + ligand	0.818/1.335	0.822/1.319	0.822/1.323
PDECIF 0.833/1.277 0.833/1.280 0.828/1.293 ECIF + ligand 0.840/1.263 0.840/1.260 0.829/1.284 PDECIF + ligand 0.843/1.252 0.840/1.258 0.844/1.248 CASF 2016—8 ECIF 0.806/1.343 0.804/1.350 0.797/1.361 PDECIF 0.823/1.303 0.829/1.290 0.824/1.305 ECIF + ligand 0.831/1.281 0.832/1.275 0.838/1.263 PDECIF + ligand 0.831/1.276 0.843/1.248 0.842/1.256 CASF 2016—10 ECIF 0.815/1.320 0.812/1.328 0.816/1.314 PDECIF 0.825/1.298 0.823/1.300 0.830/1.288 ECIF + ligand 0.842/1.252 0.844/1.246 0.839/1.260 CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF + ligand 0.842/1.235 0.853/1.239 0.851/1.249 ECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF + ligand 0.847/		PDECIF + ligand	0.841/1.272	0.840/1.273	0.839/1.275
ECIF + ligand 0.840/1.263 0.840/1.258 0.829/1.284 PDECIF + ligand 0.843/1.252 0.840/1.258 0.844/1.248 CASF 2016—8 ECIF 0.806/1.343 0.804/1.350 0.797/1.361 PDECIF 0.823/1.303 0.829/1.290 0.824/1.305 ECIF + ligand 0.831/1.281 0.832/1.275 0.838/1.263 PDECIF + ligand 0.831/1.276 0.843/1.248 0.842/1.256 CASF 2016—10 ECIF 0.815/1.320 0.812/1.328 0.816/1.314 PDECIF Bigand 0.825/1.298 0.823/1.300 0.830/1.286 ECIF + ligand 0.844/1.245 0.842/1.252 0.842/1.256 PDECIF Bigand 0.842/1.252 0.844/1.246 0.839/1.260 CASF 2019—4 ECIF Bigand 0.854/1.235 0.853/1.239 0.851/1.249 ECIF Ligand 0.854/1.235 0.853/1.239 0.851/1.249 PDECIF Bigand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF Bigand 0.859/1.234 0.850/1.240 0.849/1.241 ECIF Ligand <td>CASF 2016—6</td> <td>ECIF</td> <td>0.808/1.343</td> <td>0.811/1.335</td> <td>0.802/1.353</td>	CASF 2016—6	ECIF	0.808/1.343	0.811/1.335	0.802/1.353
CASF 2016—8 PDECIF 0.843/1.252 0.840/1.258 0.844/1.248 CASF 2016—8 ECIF 0.806/1.343 0.804/1.350 0.797/1.361 PDECIF 0.823/1.303 0.829/1.290 0.824/1.305 ECIF + ligand 0.831/1.281 0.832/1.275 0.838/1.263 PDECIF + ligand 0.831/1.276 0.843/1.248 0.842/1.256 CASF 2016—10 ECIF 0.815/1.320 0.812/1.328 0.816/1.314 PDECIF 0.825/1.298 0.823/1.300 0.830/1.288 ECIF + ligand 0.844/1.245 0.842/1.252 0.842/1.252 CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF + ligand 0.845/1.235 0.853/1.239 0.851/1.249 CASF 2019—6 ECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF + ligand 0.859/1.236 0.850/1.240 0.849/1.241 CASF 2019—8 ECIF + ligand 0.859/1.236 0.850/1.240 0.850/1.204 CASF 2019—8 ECIF + ligand 0.859/1.251		PDECIF	0.833/1.277	0.833/1.280	0.828/1.293
CASF 2016—8 ECIF 0.806/1.343 0.804/1.350 0.797/1.361 PDECIF 0.823/1.303 0.829/1.290 0.824/1.305 ECIF + ligand 0.831/1.281 0.832/1.275 0.838/1.263 PDECIF + ligand 0.831/1.276 0.843/1.248 0.842/1.256 CASF 2016—10 ECIF 0.815/1.320 0.812/1.328 0.816/1.314 PDECIF 0.825/1.298 0.823/1.300 0.830/1.288 ECIF + ligand 0.844/1.245 0.842/1.252 0.844/1.252 0.844/1.246 0.839/1.206 CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF + ligand 0.833/1.292 0.853/1.239 0.851/1.249 CASF 2019—4 ECIF 0.833/1.294 0.833/1.289 0.832/1.290 CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 CASF 2019—8 ECIF 0.859/1.236 0.860/1.240 0.859/1.201 CASF 2019—8 ECIF 0.831/1.290 0.836/1.28		ECIF + ligand	0.840/1.263	0.840/1.260	0.829/1.284
PDECIF 0.823/1.303		PDECIF + ligand	0.843/1.252	0.840/1.258	0.844/1.248
ECIF + ligand 0.831/1.281 0.832/1.275 0.838/1.262 CASF 2016—10 ECIF 0.815/1.320 0.812/1.328 0.816/1.314 PDECIF 0.825/1.298 0.823/1.300 0.830/1.288 ECIF + ligand 0.844/1.245 0.842/1.252 0.842/1.252 PDECIF + ligand 0.844/1.245 0.844/1.246 0.839/1.260 CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF 0.854/1.235 0.853/1.239 0.851/1.249 ECIF + ligand 0.833/1.294 0.833/1.289 0.832/1.290 PDECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.231 CASF 2019—78 ECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF - 0.831/1.290 0.832/1.230 0.851/1.230	CASF 2016—8	ECIF	0.806/1.343	0.804/1.350	0.797/1.361
CASF 2016—10 ECIF 0.831/1.276 0.843/1.248 0.842/1.256 CASF 2016—10 ECIF 0.815/1.320 0.812/1.328 0.816/1.314 PDECIF 0.825/1.298 0.823/1.300 0.830/1.288 ECIF + ligand 0.844/1.245 0.842/1.252 0.842/1.252 0.842/1.252 CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF 0.854/1.235 0.853/1.239 0.851/1.249 ECIF + ligand 0.833/1.294 0.833/1.289 0.832/1.290 PDECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF ligand 0.859/1.236 0.850/1.240 0.849/1.241 CASF 2019—8 ECIF ligand 0.847/1.237 0.848/1.230 0.853/1.203 CASF 2019—8 ECIF ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—10 ECIF ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF ligand 0.857/1.215		PDECIF	0.823/1.303	0.829/1.290	0.824/1.305
CASF 2016—10 ECIF 0.815/1.320 0.812/1.328 0.816/1.314 PDECIF 0.825/1.298 0.823/1.300 0.830/1.288 ECIF + ligand 0.844/1.245 0.842/1.252 0.842/1.252 PDECIF + ligand 0.844/1.245 0.844/1.246 0.839/1.260 CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF 0.854/1.235 0.853/1.239 0.851/1.249 ECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.210 CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF 0.850/1.236 0.850/1.240 0.849/1.241 ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.223 PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.204 0.854/1.222 CASF 2019—10 ECIF + ligand		ECIF + ligand	0.831/1.281	0.832/1.275	0.838/1.263
PDECIF 0.825/1.298 0.823/1.300 0.830/1.288 ECIF + ligand 0.844/1.245 0.842/1.252 0.842/1.252 PDECIF + ligand 0.842/1.252 0.844/1.246 0.839/1.260 CASF 2019—4		PDECIF + ligand	0.831/1.276	0.843/1.248	0.842/1.256
ECIF + ligand 0.844/1.245 0.842/1.252 0.842/1.256 PDECIF + ligand 0.842/1.252 0.844/1.246 0.839/1.260 CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF 0.854/1.235 0.853/1.239 0.851/1.249 ECIF + ligand 0.833/1.294 0.833/1.289 0.832/1.290 PDECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF 0.850/1.236 0.850/1.240 0.849/1.241 ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.223 PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.237 PDECIF + ligand 0.854/1.222 0.852/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF + ligand	CASF 2016—10	ECIF	0.815/1.320	0.812/1.328	0.816/1.314
CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF 0.854/1.235 0.853/1.239 0.851/1.249 ECIF + ligand 0.833/1.294 0.833/1.289 0.832/1.290 PDECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF 0.850/1.236 0.850/1.240 0.849/1.241 ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.223 PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.854/1.222 0.852/1.204 0.854/1.222 CASF 2019—10 ECIF + 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 CASF 2019—10 ECIF + 0.832/1.282		PDECIF	0.825/1.298	0.823/1.300	0.830/1.288
CASF 2019—4 ECIF 0.793/1.424 0.795/1.417 0.791/1.426 PDECIF 0.854/1.235 0.853/1.239 0.851/1.249 ECIF + ligand 0.833/1.294 0.833/1.289 0.832/1.290 PDECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF 0.850/1.236 0.850/1.240 0.849/1.241 ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.223 PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.225 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.848/1.245 0.849/1.248 0.837/1.271 PDECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.212		ECIF + ligand	0.844/1.245	0.842/1.252	0.842/1.256
PDECIF 0.854/1.235 0.853/1.239 0.851/1.249		PDECIF + ligand	0.842/1.252	0.844/1.246	0.839/1.260
ECIF + ligand 0.833/1.294 0.833/1.289 0.832/1.290 PDECIF + ligand 0.859/1.217 0.855/1.223 0.859/1.212 CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF 0.850/1.236 0.850/1.240 0.849/1.241 ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.223 PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF 0.832/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217	CASF 2019—4	ECIF	0.793/1.424	0.795/1.417	0.791/1.426
CASF 2019—6 ECIF 0.832/1.284 0.857/1.272 0.833/1.284 PDECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF 0.850/1.236 0.850/1.240 0.849/1.241 ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.223 PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217		PDECIF	0.854/1.235	0.853/1.239	0.851/1.249
CASF 2019—6 ECIF 0.832/1.284 0.837/1.272 0.833/1.284 PDECIF 0.850/1.236 0.850/1.240 0.849/1.241 ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.223 PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217		ECIF + ligand	0.833/1.294	0.833/1.289	0.832/1.290
PDECIF 0.850/1.236 0.850/1.240 0.849/1.241 ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.223 PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217		PDECIF + ligand	0.859/1.217	0.855/1.223	0.859/1.212
ECIF + ligand 0.847/1.237 0.848/1.230 0.853/1.223 PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217	CASF 2019—6	ECIF	0.832/1.284	0.837/1.272	0.833/1.284
PDECIF + ligand 0.859/1.208 0.860/1.201 0.860/1.204 CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217		PDECIF	0.850/1.236	0.850/1.240	0.849/1.241
CASF 2019—8 ECIF 0.831/1.290 0.836/1.281 0.839/1.268 PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217		ECIF + ligand	0.847/1.237	0.848/1.230	0.853/1.223
PDECIF 0.845/1.251 0.848/1.244 0.849/1.239 ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217		PDECIF + ligand	0.859/1.208	0.860/1.201	0.860/1.204
ECIF + ligand 0.854/1.222 0.852/1.230 0.851/1.227 PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217	CASF 2019—8	ECIF	0.831/1.290	0.836/1.281	0.839/1.268
PDECIF + ligand 0.857/1.215 0.862/1.204 0.854/1.222 CASF 2019—10 ECIF 0.832/1.282 0.842/1.258 0.837/1.271 PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217		PDECIF	0.845/1.251	0.848/1.244	0.849/1.239
CASF 2019—10		ECIF + ligand	0.854/1.222	0.852/1.230	0.851/1.227
PDECIF 0.848/1.245 0.849/1.248 0.851/1.236 ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217		PDECIF + ligand	0.857/1.215	0.862/1.204	0.854/1.222
ECIF + ligand 0.856/1.211 0.858/1.208 0.854/1.217	CASF 2019—10	ECIF	0.832/1.282	0.842/1.258	0.837/1.271
		PDECIF	0.848/1.245	0.849/1.248	0.851/1.236
PDECIF + ligand 0.855/1.215 0.859/1.207 0.857/1.203		ECIF + ligand	0.856/1.211	0.858/1.208	0.854/1.217
		PDECIF + ligand	0.855/1.215	0.859/1.207	0.857/1.203

selecting the best set of hyperparameters for the predictive model affects performance, and (ii) there is a difference in predictive performance between the different representations. In the first case, paired *t*-tests indicate that the difference in performance is not statistically significant when the three resampling methods are paired up and compared across all benchmark years, distances and representations. However, with a significance level of 0.01 paired *t*-tests indicate a significant difference in performance when the different dataset representations are paired and compared across the different resampling methods for the latter (table 2).

On the CASF 2019 benchmark dataset, ECIF's best performance (R/RMSE) is 0.842/1.258 and 0.858/ 1.208 without and with ligand features, respectively, both of which are at a distance of 10 Å. By contrast, PDECIF's best performance is 0.854/1.235 and 0.862/1.204 without and with ligand features, respectively, where the former is at a distance of 4 Å and the latter is at a distance of 10 Å. It is worth noting that the results for ECIF differ from those reported by Sánchez-Cruz et al. [8], where ECIF's best performance is 0.857/1.193 without ligand features, 0.866/1.169 with ligand features. In their work, the authors refer to the CASF-2019 benchmark dataset here as CASF-2016. Our results are more conservative. We believe this is the case because although the same raw files were retrieved from PDBbind, the preprocessing steps we used in generating the mol files which we then use in generating the representations differ. However, our results confirm the following findings reported in their prior work: (i) inclusion of ligand features significantly improves predictive performance, and (ii) ECIF and by extension PDECIF outperforms other state-of-the-art approaches such as convolutional neural network (CNN) architectures such as $K_{\rm DEEP}$ [3] (0.82/1.27) and TopBP-DL [18] (0.848/1.210). Furthermore, what we propose outperforms other state-of-the-art GBT-based scoring functions like AGL-Score [4] and EIC-Score [7] with Pearson R coefficients of 0.833 and 0.828 on the CASF-2016 benchmark. See tables 3 and 4 for our complete set of results.

3.2. Feature importance

We performed feature selection on the CASF 2019 benchmark training dataset with the PDECIF representation at a distance of 8 Å augmented with the ligand features, as it was the best performing (table 4). This dataset has 2912 features. The Boruta feature selection algorithm identified 817 confirmed important features. The top 20 of these features by mean importance in descending order are: C;4;3;1;0;0-C;4;3;0;1;1-h, N;3;2;1;0;0-C;4;3;0;1;1-h, O;2;1;0;0;0-C;4;3;0;1;1-h, C;4;3;0;0;0-C;4;3;0;1;1-h, C;4;2;1;1;1-C;4;3;0;1;1-h, C;4;3;0;1;1-h, C;4;3;0;1;1-h, C;4;2;0;0;0-C;4;3;0;1;1-h, C;4;2;1;1;1-h, C;4;2;0;0;0-C;4;3;0;1;1-l, Chi3v, C;4;3;0;1;1-C;4;2;1;1;1-h, C;4;1;3;0;0-C;4;3;0;1;1-l, C;4;2;1;1;1-C;4;2;1;1;1-C;4;2;1;1;1-C;4;3;0;1;1-l. The full set of important features are provided in the electronic supplementary material.

It is worth noting that 121 of the 194 ligand features we considered were selected as part of the 817 important features. Having identified these features using the training set, we performed additional experiments using just them and the same tuning configuration discussed in the previous section. The performance (*R*/RMSE) for the train–test, CV5 and CV10 resampling methods are 0.852/1.224, 0.851/1.224 and 0.849/1.228 respectively. This means that they achieve approximately 99.4%, 98.7% and 99.4% of the full dataset performance (see row 'CASF 2019—8' and entry 'PDECIF+ligand' in table 4).

4. Conclusion

In this paper, we have presented a simple extension to the ECIF representation approach for the *in silico* prediction of protein binding affinity. Our results show that the extension significantly outperforms the base approach on the CASF benchmark datasets. Furthermore, we show that for GBTs, the resampling method used in optimizing the hyperparameters affects predictive accuracy. This is particularly important when comparing against other scoring functions, where progress is measured using performance on benchmark datasets. However, our experiments show that the difference in performance gain is not statistically significant.

Data accessibility. Data and relevant code for this research work are stored in GitHub: https://github.com/oghenejokpeme/PDECIF and have been archived within the Zenodo repository: https://doi.org/10.5281/zenodo.6448428.

Authors' contributions. O.I.O.: conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft, writing—review and editing; A.A.R.: conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft, writing—review and editing; H.L.: formal analysis, investigation, writing—review and editing; H.N.: conceptualization, formal analysis, funding acquisition, project administration, supervision, writing—review and editing; R.D.K.: conceptualization, formal analysis, funding acquisition, project administration, resources, supervision, writing—review and editing.

All authors gave final approval for publication and agreed to be held accountable for the work performed therein. Conflict of interest declaration. We declare we have no competing interests.

Funding. This work was supported by the Engineering and Physical Sciences Research Council (EPSRC) UK through the ACTION on cancer grant (grant nos. EP/R022925/1, EP/R022941/1). H.N. is supported by the EPSRC under the program grant no. EP/S026347/1 and the Alan Turing Institute under the EPSRC grant no. EP/N510129/1. H.L. is

royalsocietypublishing.org/journal/rsos

R.

Soc.

Open Sci. 9: 211745

supported by University College London and the China Scholarship Council under the UCL-CSC scholarship (grant no. 201908060002).

References

- Li H, Sze KH, Lu G, Ballester PJ. 2020 Machinelearning scoring functions for structure-based drug lead optimization. Wiley Interdiscip Rev.: Comput. Mol. Sci. 10, e1465. (doi:10.1002/ wcms.1465)
- Liu J, Wang R. 2015 Classification of current scoring functions. J. Chem. Inf. Model. 55, 475–482. (doi:10.1021/ci500731a)
- Jiménez J, Skalic M, Martinez-Rosell G, De Fabritiis G. 2018 K_{DEEP}: protein—ligand absolute binding affinity prediction via 3Dconvolutional neural networks. J. Chem. Inf. Model. 58, 287—296. (doi:10.1021/acs.jcim. 7b00650)
- Nguyen DD, Wei GW. 2019 AGL-score: algebraic graph learning score for protein–ligand binding scoring, ranking, docking, and screening. J. Chem. Inf. Model. 59, 3291–3304. (doi:10. 1021/acs.jcim.9b00334)
- Su M, Yang Q, Du Y, Feng G, Liu Z, Li Y, Wang R. 2018 Comparative assessment of scoring functions: the CASF-2016 update. *J. Chem. Inf. Model.* 59, 895–913. (doi:10.1021/acs.jcim. 8b00545)
- Zheng L, Fan J, Mu Y. 2019 Onionnet: a multiplelayer intermolecular-contact-based convolutional neural network for protein—liqand binding

- affinity prediction. *ACS Omega* **4**, 15 956–15 965. (doi:10.1021/acsomega.9b01997)
- Nguyen DD, Wei GW. 2019 DG-GL: differential geometry-based geometric learning of molecular datasets. Int. J. Numer. Methods Biomed. Eng. 35, e3179. (doi:10.1002/cnm. 3179)
- Sánchez-Cruz N, Medina-Franco JL, Mestres J, Barril X. 2020 Extended connectivity interaction features: improving binding affinity prediction through chemical description. *Bioinformatics* 37, 1376–1382. (doi:10.1093/bioinformatics/ btaa982)
- King RD, Orhobor OI, Taylor CC. 2021 Cross-validation is safe to use. Nat. Mach. Intell. 3, 276–276. (doi:10.1038/s42256-021-00332-7)
- Bergstra J, Bardenet R, Bengio Y, Kégl B. 2011
 Algorithms for hyper-parameter optimization.

 Adv. Neural Inf. Process. Syst. 24.
- Wójcikowski M, Kukiełka M, Stepniewska-Dziubinska MM, Siedlecki P. 2019 Development of a protein—ligand extended connectivity (PLEC) fingerprint and its application for binding affinity predictions. *Bioinformatics* 35, 1334—1341. (doi:10.1093/bioinformatics/ bty757)

- Rogers D, Hahn M. 2010 Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742–754. (doi:10.1021/ci100050t)
- Cheng T, Li X, Li Y, Liu Z, Wang R. 2009
 Comparative assessment of scoring functions on a diverse test set. J. Chem. Inf. Model. 49, 1079–1093. (doi:10.1021/ci9000053)
- Li Y, Liu Z, Li J, Han L, Liu J, Zhao Z, Wang R. 2014 Comparative assessment of scoring functions on an updated benchmark:
 Compilation of the test set. J. Chem. Inf. Model. 54, 1700–1716. (doi:10.1021/ci500080q)
- Boyles F, Deane CM, Morris GM. 2020 Learning from the ligand: using ligand-based features to improve binding affinity prediction. Bioinformatics 36, 758–764. (doi:10.26434/ chemoxiv 8174525)
- Kursa MB, Jankowski A, Rudnicki WR. 2010 Boruta—a system for feature selection. Fundam. Inform. 101. 271–285. (doi:10.3233/Fl-2010-288)
- Breiman L. 2001 Random forests. *Mach. Learn.* 45, 5–32. (doi:10.1023/A:1010933404324)
- Cang Z, Mu L, Wei GW. 2018 Representability of algebraic topology for biomolecules in machine learning based scoring and virtual screening. *PLoS Comput. Biol.* 14, e1005929. (doi:10.1371/journal.pcbi.1005929)